Skip to main content
. Author manuscript; available in PMC: 2018 Feb 20.
Published in final edited form as: Mucosal Immunol. 2016 Jan 6;9(5):1340–1352. doi: 10.1038/mi.2015.133

Figure 4. DC targeting enhances the amplitude of anti-p24 immune responses in the GI tract compared to untargeted protein vaccination.

Figure 4

C57Bl/6 mice were immunized i.n. with polyICLC, plus either α–CD205-p24 fusion mAb or untargeted p24 protein, both delivered i.n. in a prime-boost regimen, in escalating doses of 0.5µg, 5µg and 15µg. Mean data from three independent experiments (5 mice per group) is shown in (A-C) where in response to HIV gag-p24 or p17 peptide pools, IFN-γ+CD4+ T cells were quantified in the SILP (a), lung (b) and CLP (c). Background (p17) subtracted p24 data are shown. Additionally, statistical comparisons between α-CD205-p24 fusion mAb and p24 are shown. Error bars show mean ± SD. *=p<0.05, **=p<0.01, ***=p<0.001